Guha Akash, Sahewalla Ashutosh, Killing Dilip, Thakkar Manthan, Das Gaurav, Kalita Deep Jyoti, Talukdar Abhijit
Department of Surgical Oncology, Dr B Borooah Cancer Institute, Room No. 30, Surgical OPD, Gopinathnagar, Guwahati, Assam 781016 India.
Indian J Surg Oncol. 2025 Feb;16(1):290-295. doi: 10.1007/s13193-024-02081-y. Epub 2024 Sep 7.
Surgical resection for gastric adenocarcinoma (GAC) remains the only potentially curative treatment, and the use of neoadjuvant and adjuvant therapy improves survival in patients with advanced gastric cancer. Margin-positive resection is a known poor prognostic factor. A retrospective observational study of patients undergoing radical gastrectomy of any type for GAC was done at a tertiary care cancer center in Northeast India. The study included patients who were operated on from 1 January 2017 to 31 December 2021 (5 years), and they were followed up to 31 March 2024. A total of 172 patients underwent gastrectomy of any type for GAC during the study period of which 13 patients were found to have microscopic positive (R1) histopathological margin (7.6%). The median age of the patients with positive margins was 48 years (range 27 to 69 years). The male-to-female ratio was 9:4. Ten patients (77%) had poorly differentiated or signet-ring cell carcinoma. The distal margin was the most frequent margin which was positive (84.6%). Neoadjuvant chemotherapy was used in only 23.1% patients. At the end of our study period, only 1 patient out of 13 patients was alive. Median disease-free survival (DFS) was 16.2 months (95% confidence interval 1.2 to 31.1 months). Median overall survival (OS) was 20.2 months (95% confidence interval 9.3 to 31.2 months). Patients who have microscopic positive margins after gastrectomy are found to have a high incidence of poorly differentiated or signet-ring cell carcinoma.
胃腺癌(GAC)的手术切除仍然是唯一可能治愈的治疗方法,新辅助治疗和辅助治疗的使用可提高晚期胃癌患者的生存率。切缘阳性切除是一个已知的不良预后因素。在印度东北部的一家三级癌症中心,对因GAC接受任何类型根治性胃切除术的患者进行了一项回顾性观察研究。该研究纳入了2017年1月1日至2021年12月31日(5年)期间接受手术的患者,并对他们进行随访至2024年3月31日。在研究期间,共有172例患者因GAC接受了任何类型的胃切除术,其中13例患者的组织病理学切缘镜下阳性(R1)(7.6%)。切缘阳性患者的中位年龄为48岁(范围27至69岁)。男女比例为9:4。10例患者(77%)患有低分化或印戒细胞癌。远端切缘是最常见的阳性切缘(84.6%)。仅23.1%的患者使用了新辅助化疗。在我们的研究期结束时,13例患者中只有1例存活。中位无病生存期(DFS)为16.2个月(95%置信区间1.2至31.1个月)。中位总生存期(OS)为20.2个月(95%置信区间9.3至31.2个月)。胃切除术后切缘镜下阳性的患者中,低分化或印戒细胞癌的发生率较高。